Abstract
We have used a BALB/c colonic adenocarcinoma (C-26) to evaluate the therapeutic potential of recombinant interleukin-2 (rIL-2) at high and low dosages in combination with or without lymphokine-activated killers (LAK) or tumor-specific, immune lymphocytes in either an adjuvant spontaneous or an artificial metastasis system. Most (≈80%) of the mice that underwent s.c. C-26 tumor excision were shown to die of spontaneous metastasis with lung involvement by 1-4 months after excision. Postsurgical systemic treatment with low-dose rIL-2 (3 × 104 U/day, i.p.) increased the survival rate to 31% as compared to 21% (not significant) in excised controls while administration of high-dose rIL-2 (8 × 104 U/day) led to 53% survival (P
| Original language | English |
|---|---|
| Pages (from-to) | 28-36 |
| Number of pages | 9 |
| Journal | Cancer Immunology, Immunotherapy |
| Volume | 31 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1990 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Immunology
- Cancer Research
Cite this
Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes - Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model. / Rodolfo, Monica; Salvi, Carolina; Bassi, Cinzia; Parmiani, Giorgio.
In: Cancer Immunology, Immunotherapy, Vol. 31, No. 1, 01.1990, p. 28-36.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes - Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model
AU - Rodolfo, Monica
AU - Salvi, Carolina
AU - Bassi, Cinzia
AU - Parmiani, Giorgio
PY - 1990/1
Y1 - 1990/1
N2 - We have used a BALB/c colonic adenocarcinoma (C-26) to evaluate the therapeutic potential of recombinant interleukin-2 (rIL-2) at high and low dosages in combination with or without lymphokine-activated killers (LAK) or tumor-specific, immune lymphocytes in either an adjuvant spontaneous or an artificial metastasis system. Most (≈80%) of the mice that underwent s.c. C-26 tumor excision were shown to die of spontaneous metastasis with lung involvement by 1-4 months after excision. Postsurgical systemic treatment with low-dose rIL-2 (3 × 104 U/day, i.p.) increased the survival rate to 31% as compared to 21% (not significant) in excised controls while administration of high-dose rIL-2 (8 × 104 U/day) led to 53% survival (P
AB - We have used a BALB/c colonic adenocarcinoma (C-26) to evaluate the therapeutic potential of recombinant interleukin-2 (rIL-2) at high and low dosages in combination with or without lymphokine-activated killers (LAK) or tumor-specific, immune lymphocytes in either an adjuvant spontaneous or an artificial metastasis system. Most (≈80%) of the mice that underwent s.c. C-26 tumor excision were shown to die of spontaneous metastasis with lung involvement by 1-4 months after excision. Postsurgical systemic treatment with low-dose rIL-2 (3 × 104 U/day, i.p.) increased the survival rate to 31% as compared to 21% (not significant) in excised controls while administration of high-dose rIL-2 (8 × 104 U/day) led to 53% survival (P
UR - http://www.scopus.com/inward/record.url?scp=0025098150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025098150&partnerID=8YFLogxK
U2 - 10.1007/BF01742492
DO - 10.1007/BF01742492
M3 - Article
C2 - 2306753
AN - SCOPUS:0025098150
VL - 31
SP - 28
EP - 36
JO - Cancer Immunology and Immunotherapy
JF - Cancer Immunology and Immunotherapy
SN - 0340-7004
IS - 1
ER -